Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibuprofen 5% Topical Gel for DOMS
NCT01794923Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2013
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ibuprofen in delayed onset muscle soreness (DOMS) (4 arms), sponsored by Pfizer. Primary endpoint: Change From Baseline in the Time-Weighted Sum of Muscle Soreness With Movement Over 0-24 Hours Post-Dose 1. Started Jun 2013; status: completed.
02
Drugs
ibuprofen
03
Conditions
delayed onset muscle soreness (DOMS)
Beyond the preview
Go deeper on NCT01794923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01794923.